Meeting
2021 ASCO Annual Meeting
Mutational analysis of rare insertions and deletions in exon 18 and 19 of HER2 in Chinese patients with different cancer types.
Authors
Jianwen Qin
Tianjin Chest Hospital, Tianjin, China
Jianwen Qin , Dongsheng Shi , Lijie Song , Yan Yin , Bin Liu , Xiangke Li , Minjie Yang , Ting Hou , Yuxi Zhou , Jianxing Xiang , Yan Zheng , Bihao Liu , Dejuan Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3069)
DOI
10.1200/JCO.2021.39.15_suppl.3069
Abstract #
3069
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.
First Author: Julien Mazières
Poster
2018 ASCO Annual Meeting
An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
First Author: Lore Decoster
Poster
2018 ASCO Annual Meeting
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
First Author: Zandong Yang
Poster
2017 ASCO Annual Meeting
Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study.
First Author: Wei-Chu Victoria Lai